Status:
RECRUITING
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
Chinese PLA General Hospital
Conditions:
Recurrent Hepatocellular Carcinoma
Lenvatinib
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients...
Detailed Description
The evidence of ablation combined transarterial chemoembolisation (TACE) and Lenvatinib for intermediate-stage recurrent hepatocellular carcinoma (RHCC) is limited. Patient responses to this treatment...
Eligibility Criteria
Inclusion
- 18-75 years;
- RHCC diagnosed by imaging;
- intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors);
- the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;
- absence of extrahepatic metastasis or macrovascular invasion;
- Child-Pugh class A or B;
- TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.
- life expectance \>3 months;
Exclusion
- under 18 years or over 75 years of age;
- primary intermediate-stage HCC;
- RHCC with more than six tumors, or single RHCC
- (5) RHCC \>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2028
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT06609850
Start Date
October 1 2024
End Date
October 30 2028
Last Update
December 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General hospital
Beijing, None Selected, China, 100853